Would you offer adjuvant pembrolizumab to a stage II-III adenocarcinoma of the lung who had a complete pathologic response to 4 cycles of cisplatin/pemetrexed/pembro (KN-671)?

The question posed is a central question of investigation and debate today.

In my view, the patients most likely to derive benefit from adjuvant immunotherapy after receiving neo-adjuvant chemo-immunotherapy are those with the best responses to neo-adjuvant therapy. The patients I would least likely give adjuvant PD-1/PD-L1 inhibitors to are those who achieved little benefit with neo-adjuvant chemo plus PD-1/PD-L1 inhibitors. The scenario in question represents the best-case scenario, one of a co...

For perioperative systemic therapy of NSCLC, current NCCN guidelines recommend neoadjuvant chemoimmunotherapy if patients are eligible for immune checkpoint inhibitors; the two listed options include either neoadjuvant nivolumab and platinum doublet chemotherapy every 3 weeks for 3 cycles followed by surgery, or neoadjuvant pembrolizumab and platinum doublet chemotherapy every 3 weeks for 4 cycles followed by adjuvant single agent pembrolizumab continued for one year (Forde et al., PMID 35403841...